EP0593516A4 - Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie. - Google Patents

Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie.

Info

Publication number: EP0593516A4
Authority: EP; European Patent Office
Prior art keywords: bdnf; motor neuron; methods; elements; neuron diseases
Prior art date: 1991-07-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP92912453A

Other languages

English (en)

French (fr)

Other versions

EP0593516A1 (de

EP0593516B1 (de

Inventor

Vivien Wong

Czeslaw Radziejewski

Peter Distefano

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Regeneron Pharmaceuticals Inc

Original Assignee

Max Planck Gesellschaft zur Foerderung der Wissenschaften eV

Regeneron Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-10

Filing date

1992-05-19

Publication date

1995-01-18

1992-05-19 Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV, Regeneron Pharmaceuticals Inc filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV

1992-05-19 Priority to EP96111711A priority Critical patent/EP0755682A1/de

1994-04-27 Publication of EP0593516A1 publication Critical patent/EP0593516A1/de

1995-01-18 Publication of EP0593516A4 publication Critical patent/EP0593516A4/de

2001-07-11 Application granted granted Critical

2001-07-11 Publication of EP0593516B1 publication Critical patent/EP0593516B1/de

2012-05-19 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Physical Water Treatments (AREA)
Water Treatment By Electricity Or Magnetism (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Water Treatment By Sorption (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Separation Of Suspended Particles By Flocculating Agents (AREA)
External Artificial Organs (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

EP92912453A 1991-07-10 1992-05-19 Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie Expired - Lifetime EP0593516B1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP96111711A EP0755682A1 (de)	1991-07-10	1992-05-19	Verfahren zur Behandlung von Erkrankungen motorischer Neuronen durch Mitglieder der BDNF/NT-3/NGF-Familie

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US72770491A	1991-07-10	1991-07-10
US727704		1991-07-10
PCT/US1992/004228 WO1993001300A1 (en)	1991-07-10	1992-05-19	Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP96111711A Division EP0755682A1 (de)	1991-07-10	1992-05-19	Verfahren zur Behandlung von Erkrankungen motorischer Neuronen durch Mitglieder der BDNF/NT-3/NGF-Familie
EP96111711.6 Division-Into		1996-07-19

Publications (3)

Publication Number	Publication Date
EP0593516A1 EP0593516A1 (de)	1994-04-27
EP0593516A4 true EP0593516A4 (de)	1995-01-18
EP0593516B1 EP0593516B1 (de)	2001-07-11

Family

ID=24923677

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP92912453A Expired - Lifetime EP0593516B1 (de)	1991-07-10	1992-05-19	Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie
EP96111711A Withdrawn EP0755682A1 (de)	1991-07-10	1992-05-19	Verfahren zur Behandlung von Erkrankungen motorischer Neuronen durch Mitglieder der BDNF/NT-3/NGF-Familie

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP96111711A Withdrawn EP0755682A1 (de)	1991-07-10	1992-05-19	Verfahren zur Behandlung von Erkrankungen motorischer Neuronen durch Mitglieder der BDNF/NT-3/NGF-Familie

Country Status (20)

Country	Link
EP (2)	EP0593516B1 (de)
JP (1)	JPH06509094A (de)
CN (1)	CN1065768C (de)
AT (1)	ATE202939T1 (de)
AU (2)	AU675409B2 (de)
CA (1)	CA2113083A1 (de)
DE (1)	DE69231930T2 (de)
DK (1)	DK0593516T3 (de)
ES (1)	ES2157903T3 (de)
FI (1)	FI940098A7 (de)
GR (1)	GR3036776T3 (de)
HU (1)	HUT70275A (de)
IE (1)	IE921602A1 (de)
IL (1)	IL101928A0 (de)
NO (1)	NO940084L (de)
PT (1)	PT100501A (de)
RU (1)	RU94016525A (de)
SK (1)	SK2694A3 (de)
WO (1)	WO1993001300A1 (de)
ZA (1)	ZA923639B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993025684A1 (en) *	1992-06-12	1993-12-23	Regeneron Pharmaceuticals, Inc.	Therapeutic and diagnostic methods based on neurotrophin-4 expression
FR2717496B1 (fr) *	1994-03-18	1996-04-12	Rhone Poulenc Rorer Sa	Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) *	1999-12-28	2003-06-25	潘晓东	神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
AU2001259453B2 (en)	2000-05-05	2006-08-31	Beth Israel Deaconess Medical Center	Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
WO2008156418A1 (en) *	2007-06-19	2008-12-24	Astrazeneca Ab	A method for screening or diagnosis of postpolio syndrome and fibromyalgia
MX2010001395A (es) *	2007-08-10	2010-03-10	Regeneron Pharma	Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
WO2014111525A2 (en)	2013-01-18	2014-07-24	Anaxomics Biotech, Sl	New combination therapies for treating nervous system diseases
WO2016210325A1 (en)	2015-06-26	2016-12-29	C.R. Bard, Inc.	Connector interface for ecg-based catheter positioning system
WO2023164311A2 (en) *	2022-02-28	2023-08-31	Bioincept, Llc	Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders
GB202303495D0 (en) *	2023-03-09	2023-04-26	Ucl Business Ltd	Therapy for charcot-marie-tooth disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988008848A1 (en) *	1987-05-04	1988-11-17	Baylor College Of Medicine	Method to prepare a composition for treatment of amyotrophic lateral sclerosis
WO1991003569A1 (en) *	1989-08-30	1991-03-21	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Neurotrophin-3, a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5229500A (en) *	1989-08-30	1993-07-20	Regeneron Pharmaceuticals, Inc.	Brain derived neurotrophic factor
IE903130A1 (en) *	1989-09-15	1991-03-27	Regeneron Pharma	Ciliary neurotrophic factor

1992
- 1992-05-19 RU RU94016525/14A patent/RU94016525A/ru unknown
- 1992-05-19 EP EP92912453A patent/EP0593516B1/de not_active Expired - Lifetime
- 1992-05-19 SK SK26-94A patent/SK2694A3/sk unknown
- 1992-05-19 PT PT100501A patent/PT100501A/pt not_active Application Discontinuation
- 1992-05-19 ZA ZA923639A patent/ZA923639B/xx unknown
- 1992-05-19 DE DE69231930T patent/DE69231930T2/de not_active Expired - Lifetime
- 1992-05-19 WO PCT/US1992/004228 patent/WO1993001300A1/en not_active Ceased
- 1992-05-19 CA CA2113083A patent/CA2113083A1/en not_active Abandoned
- 1992-05-19 AU AU20095/92A patent/AU675409B2/en not_active Ceased
- 1992-05-19 JP JP5502202A patent/JPH06509094A/ja active Pending
- 1992-05-19 EP EP96111711A patent/EP0755682A1/de not_active Withdrawn
- 1992-05-19 ES ES92912453T patent/ES2157903T3/es not_active Expired - Lifetime
- 1992-05-19 HU HU9400063A patent/HUT70275A/hu unknown
- 1992-05-19 CN CN92105070A patent/CN1065768C/zh not_active Expired - Fee Related
- 1992-05-19 AT AT92912453T patent/ATE202939T1/de not_active IP Right Cessation
- 1992-05-19 DK DK92912453T patent/DK0593516T3/da active
- 1992-05-19 IL IL101928A patent/IL101928A0/xx unknown
- 1992-07-01 IE IE160292A patent/IE921602A1/en not_active Application Discontinuation
1994
- 1994-01-10 FI FI940098A patent/FI940098A7/fi not_active Application Discontinuation
- 1994-01-10 NO NO940084A patent/NO940084L/no unknown
1996
- 1996-11-08 AU AU70676/96A patent/AU7067696A/en not_active Abandoned
2001
- 2001-10-03 GR GR20010401637T patent/GR3036776T3/el unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988008848A1 (en) *	1987-05-04	1988-11-17	Baylor College Of Medicine	Method to prepare a composition for treatment of amyotrophic lateral sclerosis
WO1991003569A1 (en) *	1989-08-30	1991-03-21	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Neurotrophin-3, a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor

Also Published As

Publication number	Publication date
HU9400063D0 (en)	1994-06-28
IE921602A1 (en)	1993-01-13
PT100501A (pt)	1993-09-30
AU2009592A (en)	1993-02-11
ATE202939T1 (de)	2001-07-15
GR3036776T3 (en)	2002-01-31
RU94016525A (ru)	1996-06-10
NO940084D0 (no)	1994-01-10
JPH06509094A (ja)	1994-10-13
AU7067696A (en)	1997-01-16
SK2694A3 (en)	1995-02-08
DE69231930T2 (de)	2002-04-11
AU675409B2 (en)	1997-02-06
ZA923639B (en)	1993-02-24
FI940098A7 (fi)	1994-03-10
CA2113083A1 (en)	1993-01-21
WO1993001300A1 (en)	1993-01-21
EP0755682A1 (de)	1997-01-29
EP0593516A1 (de)	1994-04-27
NO940084L (no)	1994-03-08
HUT70275A (en)	1995-09-28
IL101928A0 (en)	1992-12-30
EP0593516B1 (de)	2001-07-11
DE69231930D1 (de)	2001-08-16
DK0593516T3 (da)	2001-09-17
CN1065768C (zh)	2001-05-16
CN1071585A (zh)	1993-05-05
ES2157903T3 (es)	2001-09-01
FI940098A0 (fi)	1994-01-10

Legal Events

Date	Code	Title	Description
1994-03-10	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1994-04-27	17P	Request for examination filed	Effective date: 19940110
1994-04-27	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1994-12-07	RHK1	Main classification (correction)	Ipc: A61K 37/02
1995-01-18	A4	Supplementary search report drawn up and despatched	Effective date: 19941128
1995-01-18	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1999-04-28	17Q	First examination report despatched	Effective date: 19990315
2000-06-20	GRAG	Despatch of communication of intention to grant	Free format text: ORIGINAL CODE: EPIDOS AGRA
2000-06-28	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 38/02 A, 7A 61K 38/18 B, 7G 01N 33/53 B
2000-10-17	GRAG	Despatch of communication of intention to grant	Free format text: ORIGINAL CODE: EPIDOS AGRA
2000-10-18	GRAG	Despatch of communication of intention to grant	Free format text: ORIGINAL CODE: EPIDOS AGRA
2000-10-18	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2001-01-30	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2001-01-31	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSEN Owner name: REGENERON PHARMACEUTICALS, INC.
2001-05-24	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2001-07-11	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
2001-07-11	REF	Corresponds to:	Ref document number: 202939 Country of ref document: AT Date of ref document: 20010715 Kind code of ref document: T
2001-07-11	XX	Miscellaneous (additional remarks)	Free format text: TEILANMELDUNG 96111711.6 EINGEREICHT AM 19/07/96.
2001-07-13	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG Ref country code: CH Ref legal event code: EP
2001-08-16	REF	Corresponds to:	Ref document number: 69231930 Country of ref document: DE Date of ref document: 20010816
2001-09-01	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2157903 Country of ref document: ES Kind code of ref document: T3
2001-09-17	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3
2001-10-04	ITF	It: translation for a ep patent filed
2001-11-02	ET	Fr: translation filed
2002-01-01	REG	Reference to a national code	Ref country code: GB Ref legal event code: IF02
2002-01-31	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20010401637 Country of ref document: GR
2002-05-17	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2002-05-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2002-07-03	26N	No opposition filed
2003-06-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PUEA Owner name: REGENERON PHARMACEUTICALS, INC. Free format text: REGENERON PHARMACEUTICALS, INC.#777 OLD SAW MILL RIVER ROAD#TARRYTOWN, NY 10591-6707 (US) $ MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.#HOFGARTENSTRASSE 2#80539 MUENCHEN (DE) -TRANSFER TO- REGENERON PHARMACEUTICALS, INC.#777 OLD SAW MILL RIVER ROAD#TARRYTOWN, NY 10591-6707 (US)
2003-07-09	REG	Reference to a national code	Ref country code: GB Ref legal event code: 732E
2003-08-01	NLS	Nl: assignments of ep-patents	Owner name: REGENERON PHARMACEUTICALS, INC.
2003-10-16	REG	Reference to a national code	Ref country code: ES Ref legal event code: PC2A
2004-04-30	REG	Reference to a national code	Ref country code: FR Ref legal event code: TP
2010-07-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20100503 Year of fee payment: 19 Ref country code: LU Payment date: 20100602 Year of fee payment: 19 Ref country code: FR Payment date: 20100601 Year of fee payment: 19 Ref country code: ES Payment date: 20100526 Year of fee payment: 19 Ref country code: DK Payment date: 20100527 Year of fee payment: 19
2010-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20100524 Year of fee payment: 19 Ref country code: IT Payment date: 20100526 Year of fee payment: 19 Ref country code: DE Payment date: 20100527 Year of fee payment: 19 Ref country code: AT Payment date: 20100504 Year of fee payment: 19
2010-10-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20100525 Year of fee payment: 19 Ref country code: BE Payment date: 20100525 Year of fee payment: 19
2010-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20100527 Year of fee payment: 19 Ref country code: GB Payment date: 20100525 Year of fee payment: 19
2010-12-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GR Payment date: 20100528 Year of fee payment: 19
2011-11-30	BERE	Be: lapsed	Owner name: REGENERON PHARMACEUTICALS INC. Effective date*: 20110531
2011-12-14	REG	Reference to a national code	Ref country code: NL Ref legal event code: V1 Effective date: 20111201
2011-12-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110531
2011-12-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2012-01-09	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP
2012-01-10	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2012-01-25	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20110519
2012-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110531 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110531 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111201
2012-02-10	REG	Reference to a national code	Ref country code: GR Ref legal event code: ML Ref document number: 20010401637 Country of ref document: GR Effective date: 20111202
2012-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MM01 Ref document number: 202939 Country of ref document: AT Kind code of ref document: T Effective date: 20110519
2012-02-17	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20120131
2012-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111202 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110519 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110519
2012-03-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110531
2012-04-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 69231930 Country of ref document: DE Effective date: 20111201
2012-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110531
2012-06-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110531 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110519
2013-04-04	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20130404
2013-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110520 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110520
2013-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110519
2013-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111201

Publication	Publication Date	Title
EP0593516A4 (de)	1995-01-18	Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie.
Thornton et al.	1971	Learned helplessness in human subjects.
Pearlman et al.	1995	Trauma and the therapist: Countertransference and vicarious traumatization in psychotherapy with incest survivors.
Lyons et al.	1989	Implosive therapy for the treatment of combat-related PTSD
ES2163090T3 (es)	2002-01-16	Uso de toxina botulinica para tratar la cefalea tensional.
FI108146B (fi)	2001-11-30	Biologisesti aktiivisten, neurotrofisten NGF/BDNF-sarjan yhdistelmäproteiinien valmistus
HUP0001078A2 (hu)	2000-08-28	A retina ganglion sejt sérülésének glia sejtvonal eredetű neurotróf faktor (GDNF) protein termék felhasználásával történő kezelésére szolgáló módszer
AU6909091A (en)	1991-06-26	Neurologic agents for nasal administration to the brain
NO975234D0 (no)	1997-11-14	Fremgangsmåte for behandling av maniske og bipolare forstyrrelser
DE3782346D1 (de)	1992-12-03	Verwendung von chinolon und naphthyridin-antibiotika zur herstellung von ophthalmischen arzneimitteln.
Metter et al.	1993	Theoretical, Clinical, Research, and Ethical Constraints of the Eye Movement Desensitization Reprocessing Technique.
FI925457A0 (fi)	1992-11-30	Receptor av den ciliaera neurotrofiska faktorn
ROSENTHAL	1980	Social cueing processes
RU94039177A (ru)	1996-10-27	Способ лечения детей с первичной артериальной гипертензией 1-б стадии
EP1469734A4 (de)	2007-02-28	Verfahren zur therapeutischen verwendung von aus dem hirn stammendem neurotrophie-faktor im entorhinalkortex
Adams	1985	The obsessive child: A therapy update
DK0538690T3 (da)	1995-03-06	Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
Flowers et al.	1995	The cost of client transfer
Myers et al.	2017	The applications of neuroscience to clinical mental health counseling.
Viruega et al.	2025	How Hippotherapy Can Tackle
Dibner et al.	1962	Screening for psychotherapy by an open-ended group
Hoogduin et al.	1988	Double-Blind Research Psychotherapy
Sokolova	1995	On the problem of psychotherapy of borderline personality-disorders
EP1274452A4 (de)	2004-11-10	Methode zur prävention und behandlung von diabetes
RU97112417A (ru)	1999-06-10	Способ лечения больных хроническим описторхозом